December 21, 2014 4:51 PM ET

Pharmaceuticals

Company Overview of Amaran Biotechnology Inc.

Company Overview

Amaran Biotechnology Inc. develops and markets BOTOX drugs. The company was founded in 2010 and is based in Taipei City, Taiwan.

11F-1, No. 308, Sec. 2

BaDe Road

ZhongShan District

Taipei City,  10492

Taiwan

Founded in 2010

Key Executives for Amaran Biotechnology Inc.

Amaran Biotechnology Inc. does not have any Key Executives recorded.

Amaran Biotechnology Inc. Key Developments

Stellar Biotechnologies Announces Collaboration with Amaran Biotechnology, Inc

Stellar Biotechnologies, Inc. announced that it has entered into a collaboration agreement with Amaran Biotechnology, Inc. to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy using Stellar's GMP grade Keyhole Limpet Hemocyanin. Amaran designs, develops, and manufactures active immunotherapies such as OBI-822, the lead immunotherapy product of OBI Pharma, Inc. The primary purpose of the alliance is to develop and evaluate methods for the manufacture of the OBI-822 active immunotherapy using Stellar's GMP grade KLH. OBI-822 is a new generation of active immunotherapy combining Globo-H, a carbohydrate antigen frequently expressed by cancer cells, together with KLH as the immune-stimulating carrier molecule. An active immunotherapy uses a patient's own immune system to recognize and mount an attack against the targeted tumor cells. OBI-822 is currently being evaluated for the treatment of metastatic breast cancer in International Phase 2/3 clinical trials in the United States, Taiwan, South Korea, India and Hong Kong. It is also being evaluated for the treatment of ovarian cancer in an investigator-initiated Phase 1/2 clinical trial in Taiwan. Under the terms of the agreement, Stellar will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in OBI-822 immunotherapy. Stellar will also be responsible for method development, product formulation, and process qualification for certain KLH reference standards. Amaran will be responsible for development objectives and product specifications. The agreement provides for Amaran to pay to Stellar fees for certain expenses and costs associated with the development program. Subject to certain conditions and timing, the collaboration also provides for the companies to negotiate a commercial supply agreement for Stellar KLH(TM) in the future.

Amaran Biotechnology Inc. to Invest USD 33.41 Million in Taiwanese Factory for Botox Biosimilar

Amaran Biotechnology Inc. has announced plans to invest TWD 1 billion in a factory and research centre in Taiwan's Hsinchu Biomedical Science Park, Taipei, in relation to conducting clinical trials and manufacturing drugs developed by OBI Pharma Inc, a subsidiary of Optimer Pharmaceuticals. The new factory will initially focus on production of a biosimilar of botulinum toxin type A, otherwise known as Botox, for use in cosmetic surgery, along with other generic protein drugs, Amaran states. Amaran stated that the factory will have the capacity to produce OBI's flagship R&D hope, OBI-822, a first-in-class immunotherapy for metastatic breast cancer currently at the Phase II/III stage.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Amaran Biotechnology Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.